The movement to adopt a grading system for MTC is the result of years of research and is intended to make the care of patients with MTC more precise.
We look at how our understanding of medullary thyroid carcinoma has evolved over the last several decades, and what we now know about treating the cancer.
We take a look at epidemiological data on the global distribution of RET mutations in cases of medullary thyroid carcinoma.
We examine the lasting impact of innovative clinical trial designs for rare diseases on other clinical experiments.
We discuss the case study of a patient who was diagnosed with medullary thyroid carcinoma with paraneoplastic Cushing‘s syndrome.
We discuss current therapeutic strategies in targeting the PDGF/PDGFR signaling pathway in cancer research.
We describe the characteristics of exceedingly rare thyroid collision tumors and look at a real-world case study.
We discuss studies investigating the prognosis of MTC patients with lymph node metastases, as well as the best way to break bad news to patients.
We examine the role of the cholecystokinin-2 receptor (CCK2R) in MTC nuclear imaging, and discuss methods of targeting it more efficiently.
We explore various issues related to nephrotoxicity induced by tyrosine kinase inhibitors in patients with medullary thyroid carcinoma.